Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, the Company is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback